PainchekASX:PCK +8.25%52 Return-on-Tangible-Equity is -1,364.88% as of Dec. 2025. GuruFocus rates ASX:PCK with a GF Score™ of 52/100 and a GF Value™ of A$0.40 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 581 Healthcare Providers & Services companies, Painchek ranks worse than 98.62% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Painchek's annualized net income for the quarter that ended in Dec. 2025 was A$-9.40 Mil. Painchek's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$0.69 Mil. Therefore, Painchek's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -1,364.88%.
The historical rank and industry rank for Painchek's Return-on-Tangible-Equity or its related term are showing as below:
ASX:PCK'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -8668.93 Med: -288.19 Max: -87.56
Current: -747.85
During the past 13 years, Painchek's highest Return-on-Tangible-Equity was -87.56%. The lowest was -8,668.93%. And the median was -288.19%.
ASX:PCK's Return-on-Tangible-Equity is ranked worse than 98.62% of 581
companies
in the Healthcare Providers & Services industry
Industry Median: 9.93
vs ASX:PCK: -747.85
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Painchek Return-on-Tangible-Equity Related Terms
Painchek Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Painchek's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PCK vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Painchek's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Painchek Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Painchek's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Painchek's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -1,364.88% mean?
Painchek (ASX:PCK) has a Return-on-Tangible-Equity of -1,364.88% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Painchek and its competitors. According to the industry distribution chart, Painchek ranks #573 out of 581 companies in the Healthcare Providers & Services industry, placing it in the top 98.6%.
Is Painchek's Return-on-Tangible-Equity too high?
Painchek's current Return-on-Tangible-Equity is -1,364.88%. Based on the distribution chart, Painchek ranks #573 out of 581 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Painchek has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #573 out of 581 companies for Return-on-Tangible-Equity. This places Painchek in the lower half of its industry. The industry median Return-on-Tangible-Equity is 9.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 9.93, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Painchek and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current Return-on-Tangible-Equity is -1,364.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.11 — trading 73.8% below its estimated fair value. The current Return-on-Tangible-Equity is -1,364.88%. Painchek's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Painchek (ASX:PCK), the current Return-on-Tangible-Equity is -1,364.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Painchek (ASX:PCK) Overvalued in 2026?
Based on GuruFocus' analysis, Painchek stock appears to be undervalued.
The current stock price of A$0.11 is trading 73.8% below its estimated GF Value™ of A$0.40.
GuruFocus considers Painchek to be Possible Value Trap.
Key valuation signals for ASX:PCK:
Return-on-Tangible-Equity: -1,364.88%
GF Value™: A$0.40 vs. price of A$0.11 (73.8% below fair value)
No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
52GF Score
Get the complete analysis for ASX:PCK
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PCK has been successfully added to your 
